Koizumi Takeo, Tanaka Hideharu, Sakaki Seiki, Shimazaki Shuji
Department of Emergency and Critical Care Medicine, Medical School of Kyorin University, Tokyo, Japan.
Arch Surg. 2006 Oct;141(10):992-5. doi: 10.1001/archsurg.141.10.992.
Extensive burn injury leads to production of free radicals subsequent to massive fluid resuscitation, which in turn increases the risk of acute lung injury. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, is clinically effective in improving the prognosis after cerebral infarction. However, the effect of edaravone against extensive burn injury has not been tested. Objected To evaluate whether edaravone can reduce free radical precursors in a 30% burn model in rats.
Prospective, randomized controlled experiment.
Animal basic science laboratory.
Male Wistar rats weighing 200 to 220 g.
All rats (n = 10) were given a 30% full-thickness burn according to the Walker and Mason method. Immediately after the burn, edaravone was injected into the rats (n = 5) intraperitoneally at a dose of 9 mg/kg. One hour after burn injury, blood and tissue samples were collected to analyze free radical changes of serum and tissue malondialdehyde (MDA) and xanthine oxidase (XOD) and lung white blood cells.
Statistical significance was found between nontreatment and edaravone treatment relative to serum MDA (mean +/- SD, 2.50 +/- 0.54 vs 1.74 +/- 0.29 nmol/mL), serum XOD (mean +/- SD, 5.04 +/- 1.67 vs 2.26 +/- 0.83 U/L), tissue MDA (mean +/- SD, 1268.7 +/- 289.9 vs 569.1 +/- 135.9 nmol/mg protein), tissue XOD (mean +/- SD, 256.3 +/- 58.1 vs 50.96 +/- 19.60 mU/g tissue), lung white blood cells (mean +/- SD, 3088 +/- 1144 vs 1542 +/- 575 mU/g tissue), and lung XOD (mean +/- SD, 428.3 +/- 210.5 vs 81.8 +/- 36.0 nmol/mg protein).
Edaravone treatment induces significant reduction of free radical precursors and their metabolites compared with controls in burn rats. This suggests that edaravone could be helpful in the clinical treatment of large burns.
大面积烧伤后大量液体复苏会导致自由基产生,进而增加急性肺损伤的风险。依达拉奉(3 - 甲基 - 1 - 苯基 - 2 - 吡唑啉 - 5 - 酮)是一种新型自由基清除剂,在改善脑梗死预后方面临床效果显著。然而,依达拉奉对大面积烧伤损伤的作用尚未得到验证。目的:评估依达拉奉是否能降低大鼠30%烧伤模型中的自由基前体。
前瞻性随机对照实验。
动物基础科学实验室。
体重200至220克的雄性Wistar大鼠。
所有大鼠(n = 10)按照Walker和Mason方法给予30%全层烧伤。烧伤后立即对5只大鼠腹腔注射依达拉奉,剂量为9毫克/千克。烧伤后1小时,采集血液和组织样本,分析血清和组织丙二醛(MDA)、黄嘌呤氧化酶(XOD)的自由基变化以及肺白细胞情况。
在未治疗组和依达拉奉治疗组之间,血清MDA(均值±标准差,2.50±0.54对1.74±0.29纳摩尔/毫升)、血清XOD(均值±标准差,5.04±1.67对2.26±0.83单位/升)、组织MDA(均值±标准差,1268.7±289.9对569.1±135.9纳摩尔/毫克蛋白)、组织XOD(均值±标准差,256.3±58.1对50.96±19.60毫微单位/克组织)、肺白细胞(均值±标准差,3088±1144对1542±575毫微单位/克组织)以及肺XOD(均值±标准差,428.3±210.5对81.8±36.0纳摩尔/毫克蛋白)方面存在统计学差异。
与烧伤大鼠对照组相比,依达拉奉治疗可使自由基前体及其代谢产物显著减少。这表明依达拉奉可能有助于大面积烧伤的临床治疗。